POTELIGEO
Drug
Kyowa Kirin, Inc.
Total Payments
$3.8M
Transactions
7,024
Doctors
3,700
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $958,970 | 2,614 | 1,808 |
| 2021 | $588,289 | 1,481 | 1,132 |
| 2020 | $474,688 | 711 | 558 |
| 2019 | $1.7M | 1,959 | 893 |
| 2018 | $61,069 | 259 | 191 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 150 | 67.7% |
| Consulting Fee | $579,344 | 197 | 15.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $268,206 | 89 | 7.1% |
| Food and Beverage | $148,259 | 5,880 | 4.0% |
| Travel and Lodging | $80,422 | 340 | 2.1% |
| Education | $65,461 | 341 | 1.7% |
| Honoraria | $52,104 | 25 | 1.4% |
| Grant | $15,000 | 1 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $2,000 | 1 | 0.1% |
Payments by Type
Research
$2.5M
150 transactions
General
$1.2M
6,874 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 mogamulizumab Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma | Kyowa Kirin Pharmaceutical Development, Inc | $652,267 | 0 |
| A phase 2 single?center, single?arm, open?label Mogamulizumab combined upfront with low?dose total skin electron beam therapy (LD?TSEBT) in patients with mycosis fungoides (MF) and S?zary syndrome (SS) | Kyowa Kirin, Inc. | $323,387 | 0 |
| Post-authorisation safety study of allogeneic haematopoietic cell transplantation in patients treated with mogamulizumab | Kyowa Kirin Services Ltd | $309,438 | 0 |
| Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab KW-0761 in Adult Subjects with Locally Advanced or Metastatic Solid Tumors | Kyowa Kirin Pharmaceutical Development, Inc | $269,719 | 0 |
| Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) | Kyowa Kirin, Inc. | $262,757 | 0 |
| A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL | Kyowa Kirin, Inc. | $198,765 | 0 |
| Retrospective Analysis of Standard-of-Care Imaging in Patients with Cutaneous T-Cell Lymphoma to Develop new lymph node response criteria by using novel radiological quantitative techniques | Kyowa Kirin, Inc. | $165,000 | 0 |
| Open-Label, Multicenter Phase 12 Study of Mogamulizumab in Combination with Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumors | Kyowa Kirin Pharmaceutical Development, Inc | $156,785 | 0 |
| 21-001504 Mycosis Fungoides and Sezary Syndrome in African American | Kyowa Kirin, Inc. | $35,000 | 0 |
| Racial Disparities in Time to Treatment for Mycosis Fungoides: A Retrospective Analysis of Cases from the US National Cancer Database from 2004 - 2017 | Kyowa Kirin, Inc. | $35,000 | 0 |
| Single-cell Heterogeneity in African American Patients with Mycosis Fungoides and Sezary Syndrome | Kyowa Kirin, Inc. | $35,000 | 0 |
| 0761-016 | Kyowa Kirin, Inc. | $32,713 | 0 |
| Outcomes in African American Patients with Mycosis Fungoides | Kyowa Kirin, Inc. | $26,000 | 0 |
| The EDUCATE Initiative: The Multimodal Campaign to Enhance Provider-Patient Awareness of CTCL Disparities of Skin of Color | Kyowa Kirin, Inc. | $20,000 | 0 |
| Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors | Kyowa Kirin, Inc. | $7,455 | 0 |
| Phase 1 Study of Mogamulizumab KW-0761 in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors | Kyowa Kirin Pharmaceutical Development, Inc | $5,379 | 0 |
| KW-0761-010 | Kyowa Kirin Pharmaceutical Development, Inc | $4,909 | 0 |
| A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody KHK4083 in Subjects with Moderate to Severe Atopic Dermatitis AD | Kyowa Kirin Pharmaceutical Development, Inc | $1,300 | 1 |
Top Doctors Receiving Payments for POTELIGEO — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Dermatology | Silver Spring, MD | $10,960 | 10 |
| , M.D | Hematology | Atlanta, GA | $10,764 | 11 |
| , MD | Medical Oncology | New Haven, CT | $10,043 | 9 |
| , M.D | Dermatology | New Orleans, LA | $9,426 | 20 |
| , MD | Dermatology | New York, NY | $9,421 | 16 |
| , MD | Dermatology | New York, NY | $9,374 | 20 |
| , MD | Hematology & Oncology | Scarborough, ME | $9,302 | 10 |
| , MD, PHD | Dermatopathology | Nashville, TN | $9,147 | 10 |
| , M.D | Hematology | Winston Salem, NC | $9,145 | 13 |
| , MD | Hematology & Oncology | Waterbury, CT | $8,634 | 12 |
| , MD | Internal Medicine | New York, NY | $8,134 | 10 |
| , MD | Hematology & Oncology | Washington, DC | $8,133 | 8 |
| , MD | Specialist | New Orleans, LA | $8,102 | 14 |
| , M.D | Medical Oncology | Naples, FL | $7,859 | 9 |
| , MD | Hematology & Oncology | Los Angeles, CA | $7,830 | 7 |
| , MD | Dermatology | Troy, MI | $7,795 | 22 |
| , MD, PHD | Dermatology | Duarte, CA | $7,730 | 12 |
| , ARNP | Nurse Practitioner | Tampa, FL | $7,683 | 18 |
| , MD | Dermatology | Redwood City, CA | $7,628 | 7 |
| , MD | Medical Oncology | Saint Louis, MO | $7,397 | 7 |
| , M.D | Dermatology | Chicago, IL | $7,208 | 9 |
| , MD | Dermatology | New York, NY | $7,089 | 9 |
| , MD | Internal Medicine | Baltimore, MD | $7,075 | 10 |
| , M.D | Hematology & Oncology | Philadelphia, PA | $6,947 | 6 |
| , M.D., PH.D | Dermatology | Milwaukee, WI | $6,786 | 11 |
Ad
Manufacturing Companies
- Kyowa Kirin, Inc. $2.3M
- Kyowa Kirin Pharmaceutical Development, Inc $1.1M
- Kyowa Kirin Services Ltd $321,439
Product Information
- Type Drug
- Total Payments $3.8M
- Total Doctors 3,700
- Transactions 7,024
About POTELIGEO
POTELIGEO is a drug associated with $3.8M in payments to 3,700 healthcare providers, recorded across 7,024 transactions in the CMS Open Payments database. The primary manufacturer is Kyowa Kirin, Inc..
Payment data is available from 2018 to 2022. In 2022, $958,970 was paid across 2,614 transactions to 1,808 doctors.
The most common payment nature for POTELIGEO is "Unspecified" ($2.5M, 67.7% of total).
POTELIGEO is associated with 18 research studies, including "Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 mogamulizumab Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma" ($652,267).